MX366038B - 1, 2-dioles y 1,2,3-trioles antiespasmodicos. - Google Patents
1, 2-dioles y 1,2,3-trioles antiespasmodicos.Info
- Publication number
- MX366038B MX366038B MX2014014634A MX2014014634A MX366038B MX 366038 B MX366038 B MX 366038B MX 2014014634 A MX2014014634 A MX 2014014634A MX 2014014634 A MX2014014634 A MX 2014014634A MX 366038 B MX366038 B MX 366038B
- Authority
- MX
- Mexico
- Prior art keywords
- triols
- diols
- antispasmodic
- agents
- inflammatory
- Prior art date
Links
- 230000002921 anti-spasmodic effect Effects 0.000 title abstract 2
- 239000000812 cholinergic antagonist Substances 0.000 title abstract 2
- 150000000180 1,2-diols Chemical class 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 208000021017 Weight Gain Diseases 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que comprenden 1,2-dioles alifáticos C4-C8 y 1, 2, 3-trioles alifáticos C4-C8 y su uso para aliviar los espasmos asociados con el dolor. Estos agentes pueden ser administrados tópica u oralmente y pueden combinarse con agentes antiinflamatorios tales como un fármaco antiinflamatorio no esteroideo o corticoesteroide. La administración de los 1 ,2-dioles alifáticos C4-C8 y 1,2,3-trioles alifáticos C4-C8 con vitamina D3 es indicada para condiciones tales como pérdida ósea, aumento de peso y enfermedades autoinmunes tales como lupus y artritis reumatoide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653737P | 2012-05-31 | 2012-05-31 | |
US13/798,822 US8853189B2 (en) | 2012-05-31 | 2013-03-13 | Antispasmodic 1,2-Diols and 1,2,3-triols |
PCT/US2013/042583 WO2013181084A1 (en) | 2012-05-31 | 2013-05-24 | Antispasmodic 1,2-diols and 1,2,3-triols |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014014634A MX2014014634A (es) | 2015-08-06 |
MX366038B true MX366038B (es) | 2019-06-25 |
Family
ID=49670995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014634A MX366038B (es) | 2012-05-31 | 2013-05-24 | 1, 2-dioles y 1,2,3-trioles antiespasmodicos. |
Country Status (8)
Country | Link |
---|---|
US (2) | US8853189B2 (es) |
EP (1) | EP2854782B1 (es) |
JP (1) | JP5890939B2 (es) |
BR (1) | BR112014029691B1 (es) |
CA (1) | CA2874961C (es) |
MX (1) | MX366038B (es) |
RU (1) | RU2657556C2 (es) |
WO (1) | WO2013181084A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7025129B2 (ja) * | 2017-05-17 | 2022-02-24 | 小林製薬株式会社 | 筋痙攣治療剤 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1276097A (en) | 1968-09-09 | 1972-06-01 | Orsymonde | Improvements in or relating to phloroglucinol derivatives |
FR2068442A1 (en) | 1969-11-24 | 1971-08-27 | Buzas Andre | Diproqualone camphosulphonate noramidopyrine mixtures - having analgesic properties |
US4076937A (en) | 1973-12-17 | 1978-02-28 | Warner-Lambert Company | Dibenzyl glycolic acid derivatives |
US4119730A (en) | 1976-05-18 | 1978-10-10 | Chimicasa Gmbh | Treating muscle spasms |
CA1165240A (en) | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
US4677101A (en) | 1983-09-26 | 1987-06-30 | Merck & Co., Inc. | Substituted dihydroazepines useful as calcium channel blockers |
CA2112751A1 (en) * | 1991-07-03 | 1993-01-21 | Charles J. Ii Betlach | Composition and method for transdermal delivery of diclofenac |
EG20380A (en) | 1991-10-16 | 1999-02-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
JP3526887B2 (ja) | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
CA2259316A1 (en) | 1996-07-01 | 1998-01-08 | Bridge Pharma, Inc. | Smooth muscle spasmolytic agents, compositions and methods of use thereof |
EP0868915A1 (en) | 1997-04-02 | 1998-10-07 | Panacea Biotec Limited | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium |
WO2002051395A1 (en) | 1998-05-28 | 2002-07-04 | Codon Pharmaceuticals, Inc. | Treatment of neurodegenerative diseases |
HUP9802716A3 (en) | 1998-11-25 | 2000-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition of analgesic activity |
DK1194109T3 (da) | 1999-06-25 | 2004-10-25 | Durham Pharmaceuticals Ltd | Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20040151771A1 (en) | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
ATE545627T1 (de) | 2003-05-23 | 2012-03-15 | Bridge Pharma Inc | Glattmuskelspasmolytika |
US20060018867A1 (en) | 2004-05-12 | 2006-01-26 | Ichimaru Pharcos Co., Ltd | Cosmetic composition and production thereof |
WO2006044290A2 (en) | 2004-10-12 | 2006-04-27 | Board Of Trustees Of Michigan State University | Biosynthesis of philoroglucinol and preparation of 1,3-dihydroxybenzene therefrom |
KR20070093079A (ko) | 2004-11-29 | 2007-09-17 | 암브리아 더마톨로지 아베 | 적어도 세 개의 다른 디올을 포함하는 조성물 |
EP1898880A2 (en) | 2005-06-16 | 2008-03-19 | Warner Chilcott Company Inc. | Gel compositions for topical administration |
US8318973B2 (en) | 2005-10-21 | 2012-11-27 | Bezwada Biomedical, Llc | Functionalized sinapic acid and methyl sinapate |
WO2007098135A2 (en) | 2006-02-21 | 2007-08-30 | Inolex Investment Corporation | Anti-microbial compositions |
BRPI0717769A2 (pt) | 2006-10-17 | 2013-11-05 | Nuvo Res | Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio |
EP2514407A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
PL3075401T3 (pl) | 2007-11-29 | 2024-08-19 | Inolex Investment Corporation | Środek konserwujący dla kompozycji kosmetycznych, toaletowych i farmaceutycznych |
US20090182054A1 (en) * | 2008-01-10 | 2009-07-16 | Jerry Zhang | Topical compositions containing solubilized dicarboxylic acids |
ES2391913T3 (es) | 2008-06-13 | 2012-12-03 | Clariant Finance (Bvi) Limited | Composiciones cosméticas o farmacéuticas que comprenden polisiloxanos modificados con al menos un grupo carbamato |
AU2009310437A1 (en) | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
SG10201401297QA (en) | 2009-04-08 | 2014-08-28 | Cadila Healthcare Ltd | Stable pharmaceutical compositions of diclofenac |
US20120213717A1 (en) | 2011-02-18 | 2012-08-23 | Mcneil-Ppc, Inc. | Soothing Agents |
KR102058256B1 (ko) | 2011-06-17 | 2020-01-22 | 버그 엘엘씨 | 흡입성 약제학적 조성물들 |
-
2013
- 2013-03-13 US US13/798,822 patent/US8853189B2/en active Active
- 2013-05-24 RU RU2014154402A patent/RU2657556C2/ru active
- 2013-05-24 JP JP2015515082A patent/JP5890939B2/ja active Active
- 2013-05-24 CA CA2874961A patent/CA2874961C/en active Active
- 2013-05-24 WO PCT/US2013/042583 patent/WO2013181084A1/en active Application Filing
- 2013-05-24 MX MX2014014634A patent/MX366038B/es active IP Right Grant
- 2013-05-24 EP EP13727489.0A patent/EP2854782B1/en active Active
- 2013-05-24 BR BR112014029691-0A patent/BR112014029691B1/pt active IP Right Grant
-
2014
- 2014-08-22 US US14/466,634 patent/US20140364401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2854782B1 (en) | 2018-01-31 |
RU2657556C2 (ru) | 2018-06-14 |
JP2015518046A (ja) | 2015-06-25 |
EP2854782A1 (en) | 2015-04-08 |
US20130324504A1 (en) | 2013-12-05 |
US20140364401A1 (en) | 2014-12-11 |
CA2874961A1 (en) | 2013-12-05 |
WO2013181084A1 (en) | 2013-12-05 |
RU2014154402A (ru) | 2016-07-20 |
JP5890939B2 (ja) | 2016-03-22 |
MX2014014634A (es) | 2015-08-06 |
BR112014029691A2 (es) | 2017-08-22 |
BR112014029691B1 (pt) | 2022-07-12 |
CA2874961C (en) | 2021-02-09 |
US8853189B2 (en) | 2014-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015017215A (es) | Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio. | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
IN2014DN09434A (es) | ||
IN2014DN09352A (es) | ||
IN2014DN09348A (es) | ||
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
BRPI0806713A8 (pt) | Composições de tiacumicinas estáveis | |
SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
IN2014DN09347A (es) | ||
WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
WO2012129077A3 (en) | Peptides for suppressing inflammation | |
PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
EA201291335A1 (ru) | Фармацевтические композиции для местного применения | |
MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
IN2015DN02999A (es) | ||
BR112014015578A2 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
MX366038B (es) | 1, 2-dioles y 1,2,3-trioles antiespasmodicos. | |
TW201613606A (en) | Therapeutic drug for chronic renal failure | |
MX2018011142A (es) | Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |